Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial

Research output: Contribution to journalArticle (Academic Journal)peer-review

Original languageEnglish
Article numbere083582
JournalBMJ Open
Volume14
Issue number2
Early online date5 Feb 2024
DOIs
Publication statusE-pub ahead of print - 5 Feb 2024

Bibliographical note

Funding Information:
This is independent research funded by EME and carried out at the National Institute for Health and Care Research (NIHR) Sheffield Biomedical Research Centre (NIHR203321). The views expressed are those of the authors and not necessarily those of EME, the NIHR or the Department of Health and Social Care. The authors would like to acknowledge the crucial roles of the trial steering committee, data monitoring and ethics committee as well as all site PIs.

Funding Information:
This project (StarMS: 16/126/26) is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership. The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NIHR or the Department of Health and Social Care.

Publisher Copyright:
© Author(s) (or their employer(s)) 2024.

Cite this